Precision BioSciences, iECURE Ink Licensing Pact For Gene Editing Therapies

Precision BioSciences Inc DTIL and iECURE announced a license and collaboration agreement.
Under the agreement iECURE plans to advance Precision's PBGENE-PCSK9 candidate into Phase 1 studies and gain access to Precision's PCSK9-directed ARCUS nuclease to develop additional gene-editing therapies for genetic diseases, initially targeting liver diseases.
iECURE plans to file a clinical trial application in 2022 to advance the PBGENE-PCSK9 through Phase 1 studies for familial hypercholesterolemia (FH).
Precision will retain rights to PBGENE-PCSK9.
In return, Precision has granted iECURE a license to use its PCSK9-directed ARCUS nuclease to insert genes into the well-characterized PCSK9 locus to develop treatments for four other pre-specified rare genetic diseases.
Precision will receive an equity stake in iECURE and is eligible to receive milestone and royalty payments.
Read Next: Precision BioSciences, Tiziana Life Ink Foralumab Deal For Cancer Indications.
Price Action: DTIL stock is up 5.54% at $13.33 during the market session on the last check Thursday.